SSA
TEVA icon

Schonfeld Strategic Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,209
Closed -$624K – 2577
2025
Q2 		$624K Buy
+37,209
New +$600K ﹤0.01% 1477
2024
Q3 		– Sell
-47,417
Closed -$771K – 2416
2024
Q2 		$771K Sell
47,417
-104,883
-69% -$1.62M 0.01% 1313
2024
Q1 		$2.15M Buy
+152,300
New +$1.92M 0.01% 973
2023
Q4 		– Sell
-1,100,757
Closed -$11.2M – 2204
2023
Q3 		$11.2M Buy
1,100,757
+267,125
+32% +$2.49M 0.09% 318
2023
Q2 		$6.28M Buy
833,632
+793,632
+1,984% +$6.44M 0.05% 442
2023
Q1 		$354K Sell
40,000
-2,297,200
-98% -$22.7M ﹤0.01% 1300
2022
Q4 		$21.3M Buy
2,337,200
+445,812
+24% +$3.89M 0.18% 157
2022
Q3 		$15.3M Buy
1,891,388
+361,379
+24% +$3.2M 0.13% 225
2022
Q2 		$11.5M Buy
1,530,009
+397,683
+35% +$3.46M 0.11% 238
2022
Q1 		$10.6M Buy
1,132,326
+628,026
+125% +$5.24M 0.1% 255
2021
Q4 		$4.04M Sell
504,300
-414,600
-45% -$3.74M 0.04% 520
2021
Q3 		$8.95M Buy
918,900
+301,800
+49% +$2.83M 0.09% 287
2021
Q2 		$6.11M Buy
617,100
+252,100
+69% +$2.67M 0.07% 408
2021
Q1 		$4.21M Buy
+365,000
New +$4.19M 0.05% 469
2020
Q4 		– Sell
-150,687
Closed -$1.36M – 1883
2020
Q3 		$1.36M Sell
150,687
-484,413
-76% -$5.12M 0.03% 618
2020
Q2 		$7.83M Buy
635,100
+518,800
+446% +$5.87M 0.2% 143
2020
Q1 		$1.04M Buy
116,300
+85,500
+278% +$876K 0.07% 356
2019
Q4 		$302K Buy
+30,800
New +$275K 0.01% 958
2019
Q3 		– Sell
-126,400
Closed -$1.17M – 1233
2019
Q2 		$1.17M Buy
126,400
+101,400
+406% +$1.22M 0.04% 409
2019
Q1 		$392K Sell
25,000
-363,175
-94% -$6.4M 0.01% 765
2018
Q4 		$5.99M Buy
388,175
+178,175
+85% +$3.65M 0.23% 114
2018
Q3 		$4.52M Buy
210,000
+86,500
+70% +$2.01M 0.2% 147
2018
Q2 		$3M Buy
123,500
+77,995
+171% +$1.59M 0.16% 206
2018
Q1 		$777K Buy
45,505
+20,513
+82% +$401K 0.06% 384
2017
Q4 		$473K Buy
+24,992
New +$376K 0.04% 473
2017
Q2 		– Sell
-13,953
Closed -$448K – 770
2017
Q1 		$448K Buy
+13,953
New +$476K 0.04% 389
2016
Q4 		– Sell
-23,862
Closed -$1.1M – 649
2016
Q3 		$1.1M Buy
+23,862
New +$1.24M 0.19% 154
2016
Q2 		– Sell
-41,876
Closed -$2.24M – 528
2016
Q1 		$2.24M Buy
+41,876
New +$2.46M 0.91% 18

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Schonfeld Strategic Advisors's TEVA Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 37,209 shares — an estimated $624K sold.

Schonfeld Strategic Advisors first reported a position in TEVA in Q1 2016 and held it in 28 quarters. The position peaked at $21.3M in Q4 2022. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 37,209 Teva Pharmaceuticals shares in Q3 2025, an estimated $624K.
  • Schonfeld Strategic Advisors first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 28 quarters.
  • Schonfeld Strategic Advisors's Teva Pharmaceuticals position peaked at $21.3M in Q4 2022.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.